Document Detail

Safety of low-dose oral dantrolene sodium on hepatic function.
MedLine Citation:
PMID:  21878205     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVE: To investigate the incidence of hepatobiliary dysfunction after administration of low-dose dantrolene sodium.
DESIGN: A retrospective survey of medical records.
SETTING: One secondary and 2 tertiary hospitals.
PARTICIPANTS: Patients (N=243; 144 men, 27 children; mean age ± SD, 47.8±19.7y) who were administered dantrolene at a daily dose of 12.5 to 400mg for more than 4 weeks.
INTERVENTIONS: Not applicable.
MAIN OUTCOME MEASURES: Liver function test (LFT) results, including serum total bilirubin, aspartate transaminase, alanine transaminase, and alkaline phosphatase, were recorded before and at least 1 month after the initial dose of dantrolene. In cases of treatment cessation, the reason was investigated. Significantly elevated LFT levels were defined as ≥ to 2 times the upper limit of the normal range.
RESULTS: Treatment duration was 268.0±428.5 days with a daily dose of 65.2±44.7mg. At the end of the investigation, 95 patients (39.1%) had been lost to follow-up, and 105 (43.2%) had stopped treatment. The reasons for cessation were improved spasticity (42.9%), no effect of the medication (27.6%), weakness (6.7%), and other medical problems (5.7%). Patients with weaknesses did not have elevated LFT values. A 32-year-old man with head injuries and multiple trauma developed hepatic dysfunction 82 days after the initial dose and 43 days after a dose increment to 400mg/d. Other patients did not experience significant LFT abnormalities.
CONCLUSIONS: One case of hepatic dysfunction was recorded in 243 cases after at least 4 weeks of low-dose oral dantrolene administration. Low-dose dantrolene can be used safely with meticulous clinical and laboratory monitoring.
Jung Yoon Kim; Sewoong Chun; Moon Suk Bang; Hyung-Ik Shin; Shi-Uk Lee
Related Documents :
21783755 - Flame retardant tetrabromobisphenol a induced hepatic changes in icr male mice.
6933895 - Lysozyme (muramidase) and hemolytic complement (ch50u) in sera of beagle dogs and minip...
21378205 - P-glycoprotein (abcb1) transports the primary active tamoxifen metabolites endoxifen an...
21507815 - Dosing low molecular weight heparins in kidney disease.
8870895 - Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and s...
2073685 - Dose and duration related methylmercury deposition, glycosidases inhibition, myelin deg...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of physical medicine and rehabilitation     Volume:  92     ISSN:  1532-821X     ISO Abbreviation:  Arch Phys Med Rehabil     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985158R     Medline TA:  Arch Phys Med Rehabil     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1359-63     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul, Korea; Department of Rehabilitation Medicine, Seoul National University Hospital, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of burst-type transcutaneous electrical nerve stimulation on cervical range of motion and la...
Next Document:  Tongue-based biofeedback for balance in stroke: results of an 8-week pilot study.